Neal Shore, MD
Enriched profileMedical Director, Carolina Urologic Research Center; Chief Medical Officer of Urology/Surgical Oncology, GenesisCare US · Carolina Urologic Research Center
Neal Shore is Medical Director, Carolina Urologic Research Center; Chief Medical Officer of Urology/Surgical Oncology, GenesisCare US at Carolina Urologic Research Center. OpenAlex indexes 1,294 publications with 46,560 citations (h-index 85); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. Clarivate lists Neal Shore as a Highly Cited Researcher (Clinical Medicine, 2025).
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Neal D. Shore, DR, is Medical Director, Carolina Urologic Research Center. The public record shows 1,294 publications with 46,560 citations (h-index 85), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 95 companies.
- Most recent indexed publication: 2026 · Future oncology (London, England)
- Top research focus: Prostate Cancer Treatment and Research
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 95 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 69 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 385.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.gov ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Flare Therapeutics Inc.
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Sponsor: K36 Therapeutics, Inc.
Industry payments
Updated 27 Aug 2026
95 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20258 payments$155,000openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202532 payments$75,993openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202528 payments$50,892openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
67.7%PD-1 inhibitor59.2%Pembrolizumab100%Part B, office-administered≥11 patientsGonadotropin Releasing Hormone Receptor Antagonist2.3%Orgovyx94%Firmagon6%Part D<11 patientsMusculoskeletal
25.2%RANK Ligand Inhibitor25.2%Denosumab100%Prolia0%Part D + Part B<11 patientsGenitourinary & hormones
5.3%alpha-Adrenergic Blocker2.8%Tamsulosin Hcl93%Alfuzosin Hcl Er7%Part D<11 patients5-alpha Reductase Inhibitor1.5%Finasteride100%Part D≥63 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice.
Future oncology (London, England)
Article2026 - Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.
Cancer research communications
Clinical Trial2026 - Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer.
International journal of clinical oncology
Review2026 - Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.
Prostate cancer and prostatic diseases
Article2026 - Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer5,495 citations2010
- 02Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy4,583 citations2012
- 03Olaparib for Metastatic Castration-Resistant Prostate Cancer2,246 citations2020
- 04
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/neal-shore-md-6657c17f
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/neal-shore
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Neal-Shore
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/CURCMB
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
eaupodcasts.buzzsprout.com/1555850/episodes/17056699-aua-2025-special-dr-neal-shore-discusses-phase-3-crest-study-results
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →eaupodcasts.buzzsprout.com ↗ - Other
urotoday.com/video-lectures/expert-voice/video/1141-the-next-big-thing-in-prostate-cancer-neal-shore-alicia-morgans-and-charles-ryan.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- General Surgery / Urology residency
New York Hospital-Cornell Medical Center (1984-1990); Chief Resident (1989-1990); surgical rotation at Memorial Sloan-Kettering Cancer Center
1990verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atlanticurologyclinics.com ↗ - MD
Duke University School of Medicine (1984; one independent directory source (Doximity) lists 1983, minor discrepancy across self-reported vs. directory-scraped sources …
1983verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atlanticurologyclinics.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atlanticurologyclinics.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atlanticurologyclinics.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lugpa.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atlanticurologyclinics.com ↗
- Chief Medical Officer of Urology/Surgical Oncology
GenesisCare US
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →claritypharmaceuticals.com ↗ - Past President
LUGPA (Large Urology Group Practice Association), independently reconfirmed via LUGPA's own current bio page ("a past president of LUGPA") …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lugpa.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- LUGPA Presidential Citation (November 2023)
recognizing lifetime achievements establishing LUGPA's Continuing Medical Education programs
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lugpa.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atlanticurologyclinics.com ↗
Secondary affiliations
appointments beyond the home institution- Member
Clinical Advisory Board, Clarity Pharmaceuticals (joined May 26, 2022); Principal Investigator for Clarity's COBRA prostate-cancer imaging trial
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →claritypharmaceuticals.com ↗ - Board of Directors: Photocure
Alessa Therapeutics, Bladder Cancer Advocacy Network (BCAN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atlanticurologyclinics.com ↗ - Executive Board
Society of Urologic Oncology Clinical Trials Consortium
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lugpa.org ↗
Media & interviews
press, podcasts and appearances- OncLive On Air podcast / video series
recurring guest discussing prostate and bladder cancer treatment strategies
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Urology Care Foundation Podcast
"Genetic and Biomarker Testing for Bladder Cancer with Dr. Neal Shore"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urologyhealth.org ↗ - Talking Urology Podcast (Australia)
"Talking Urology and Raiders of the Lost CRPC" featuring Neal Shore and Ben Tran
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →talkingurology.com.au ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Sherertz, MD
Carolina Urologic Research Center
Donald Eagerton, MD
Carolina Urologic Research Center
Rami Khouzam, MD
Carolina Urologic Research Center